A Phase II Study of the Efficacy and Safety of Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer After Treatment With Pd-1 or Pd-L1 Inhibitors
Phase of Trial: Phase II
Latest Information Update: 28 Feb 2018
At a glance
- Drugs Axitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 24 Feb 2018 Planned number of patients changed from 50 to 38.
- 24 Feb 2018 Planned End Date changed from 1 Sep 2018 to 1 Sep 2019.
- 24 Feb 2018 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2018.